Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC50
= 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila
model of Huntington's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Campesan et al.
Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni et al.
Structural basis of kynurenine 3-monooxygenase inhibition.
Amaral et al.
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori et al.